Free Trial
NASDAQ:SGMT

Sagimet Biosciences Q4 2024 Earnings Report

Sagimet Biosciences logo
$8.25 -0.44 (-5.06%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$8.39 +0.14 (+1.68%)
As of 08/1/2025 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sagimet Biosciences EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.65
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Sagimet Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sagimet Biosciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 12, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

Sagimet Biosciences' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Sagimet Biosciences Earnings Headlines

Analysts Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $26.83
Too busy to trade? Good.
Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at screens all day. Just enter near the close, exit the next morning—and move on. Some trades have hit 200%+ overnight.
SGMT Sagimet Biosciences Inc. - Seeking Alpha
See More Sagimet Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sagimet Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sagimet Biosciences and other key companies, straight to your email.

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ:SGMT), a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

View Sagimet Biosciences Profile

More Earnings Resources from MarketBeat